Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure

Today, there is continued, and in some cases growing, availability of not only psychoactive substances, including treatments for mental health disorders such as cognitive enhancers, which can enhance or restore brain function, but also ‘recreational’ drugs such as novel psychoactive substances (NPS). The use of psychoactive drugs has both benefits and risks: whilst new drugs to treat cognitive symptoms in neuropsychiatric or neurodegenerative disorders could have great benefits for many patient groups, the increasing ease of accessibility to recreational NPS and the increasing lifestyle use of cognitive enhancers by healthy people means that the effective management of psychoactive substances will be an issue of increasing importance. Clearly, the potential benefits of cognitive enhancers are large and increasingly relevant, particularly as the population ages, and for this reason, we should continue to devote resources to the development of cognitive enhancers as treatments for neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease, attention deficit hyperactivity disorder and schizophrenia. However, the increasing use of cognitive enhancers by healthy individuals raises safety, ethical and regulatory concerns, which should not be ignored. Similarly, understanding the short‐ and long‐term consequences of the use of NPS, as well as better understanding the motivations and profiles of users could promote more effective prevention and harm reduction measures.

[1]  S. Colcombe,et al.  Fitness Effects on the Cognitive Function of Older Adults: A Meta-Analytic Study—Revisited , 2018, Perspectives on psychological science : a journal of the Association for Psychological Science.

[2]  J. Suckling,et al.  Focusing the Neuroscience and Societal Implications of Cognitive Enhancers , 2017, Clinical pharmacology and therapeutics.

[3]  A. Zalesky,et al.  Abnormal white matter integrity in synthetic cannabinoid users , 2016, European Neuropsychopharmacology.

[4]  J. Rossi,et al.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration. , 2016, Experimental and clinical psychopharmacology.

[5]  L. Clark,et al.  Games in the Brain , 2016, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[6]  A. Kjellgren,et al.  The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. , 2016, The International journal on drug policy.

[7]  M. A. De Luca,et al.  Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants , 2016, Front. Neurosci..

[8]  L. Parsons,et al.  Keep off the grass? Cannabis, cognition and addiction , 2016, Nature Reviews Neuroscience.

[9]  B. Sahakian,et al.  Drugs, games, and devices for enhancing cognition: implications for work and society , 2016, Annals of the New York Academy of Sciences.

[10]  M. Moyer A Safe Drug to Boost Brainpower , 2016 .

[11]  J. Ramsey,et al.  Up: The rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use , 2016, Journal of psychopharmacology.

[12]  Ruairidh M. Battleday,et al.  Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review , 2016, European Neuropsychopharmacology.

[13]  Christopher Southan,et al.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes , 2015, British journal of pharmacology.

[14]  Christopher Southan,et al.  The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors , 2015, British journal of pharmacology.

[15]  Christopher Southan,et al.  The Concise Guide to PHARMACOLOGY 2015/16: Ligand‐gated ion channels , 2015, British journal of pharmacology.

[16]  S. Martins,et al.  Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. , 2015, Drug and alcohol dependence.

[17]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..

[18]  G. Fond,et al.  Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review , 2015, Psychiatry Research.

[19]  John Suckling,et al.  The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  M. Rossor,et al.  Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia? , 2015, The Lancet.

[21]  B. Sahakian,et al.  The increasing lifestyle use of modafinil by healthy people: safety and ethical issues , 2015, Current Opinion in Behavioral Sciences.

[22]  C. Hillman,et al.  Physical activity, brain, and cognition , 2015, Current Opinion in Behavioral Sciences.

[23]  R. Borschmann,et al.  Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample , 2015, Journal of psychopharmacology.

[24]  Laura Orsolini,et al.  Mind Navigators of Chemicals' Experimenters? A Web-Based Description of E-Psychonauts , 2015, Cyberpsychology Behav. Soc. Netw..

[25]  F. Measham,et al.  New psychoactive substances and British drug policy: A view from the cyber-psychonauts , 2015 .

[26]  B. Sahakian,et al.  Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. , 2015, The lancet. Psychiatry.

[27]  J. Palamar,et al.  Synthetic cannabinoid use in a nationally representative sample of US high school seniors. , 2015, Drug and alcohol dependence.

[28]  Bas M. J. Olthof,et al.  A survey of substance use for cognitive enhancement by university students in the Netherlands , 2015, Front. Syst. Neurosci..

[29]  L. Orsolini,et al.  Novel psychoactive substances of interest for psychiatry , 2015, World psychiatry : official journal of the World Psychiatric Association.

[30]  Marilyn A Huestis,et al.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. , 2014, Drug and alcohol dependence.

[31]  I. Singh,et al.  Robust Resilience and Substantial Interest: A Survey of Pharmacological Cognitive Enhancement among University Students in the UK and Ireland , 2014, PloS one.

[32]  Anna Richardson,et al.  New psychoactive substances in England: a review of the evidence. , 2014 .

[33]  T. Driscoll,et al.  Pharmacological interventions for sleepiness and sleep disturbances caused by shift work , 2014, The Cochrane database of systematic reviews.

[34]  Nora D Volkow,et al.  Adverse health effects of marijuana use. , 2014, The New England journal of medicine.

[35]  Angela Me,et al.  World Drug Report 2014 , 2014 .

[36]  M. Keshavan,et al.  Cognitive training in mental disorders: update and future directions. , 2014, The American journal of psychiatry.

[37]  P. Dargan,et al.  The European Drug Emergencies Network (Euro-DEN) , 2014, Clinical toxicology.

[38]  E. Hildt,et al.  Life context of pharmacological academic performance enhancement among university students – a qualitative approach , 2014, BMC medical ethics.

[39]  M. Liechti,et al.  To Dope or Not to Dope: Neuroenhancement with Prescription Drugs and Drugs of Abuse among Swiss University Students , 2013, PloS one.

[40]  P. Kardas,et al.  [Prevalence, reasons, and forms of use of legal highs by internet-based survey participants]. , 2013, Psychiatria polska.

[41]  Irena P. Ilieva,et al.  Enhancement stimulants: perceived motivational and cognitive advantages , 2013, Front. Neurosci..

[42]  John Suckling,et al.  A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment , 2013, Brain : a journal of neurology.

[43]  D. D’Souza,et al.  Spicing things up: synthetic cannabinoids , 2013, Psychopharmacology.

[44]  F. Schifano,et al.  “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report , 2013, Human psychopharmacology.

[45]  B. Sahakian,et al.  Bad Moves: How decision making goes wrong, and the ethics of smart drugs , 2013 .

[46]  P. Simon,et al.  Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons , 2013, BMC Medicine.

[47]  Barbara J. Sahakian,et al.  Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain , 2013, Neuropharmacology.

[48]  T. Robbins,et al.  Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers , 2013, Neuropharmacology.

[49]  Scott Vrecko Just How Cognitive Is “Cognitive Enhancement”? On the Significance of Emotions in University Students' Experiences with Study Drugs , 2013, AJOB neuroscience.

[50]  C. Davidson New psychoactive substances , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[51]  S. Gruber,et al.  Age of onset of marijuana use and executive function. , 2012, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[52]  Richie Poulton,et al.  Persistent cannabis users show neuropsychological decline from childhood to midlife , 2012, Proceedings of the National Academy of Sciences.

[53]  A. Darzi,et al.  Effect of Pharmacological Enhancement on the Cognitive and Clinical Psychomotor Performance of Sleep-Deprived Doctors: A Randomized Controlled Trial , 2012, Annals of surgery.

[54]  W. Hall,et al.  Smart Drugs “As Common As Coffee”: Media Hype about Neuroenhancement , 2011, PloS one.

[55]  M. E. Smith,et al.  Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. , 2011, Psychological bulletin.

[56]  W. Fratta,et al.  Beyond THC: The New Generation of Cannabinoid Designer Drugs , 2011, Front. Behav. Neurosci..

[57]  Europäische Kommission Flash Eurobarometer 158 (Young people and drugs) , 2011 .

[58]  B. Abler,et al.  Neural Correlates of Error Monitoring Modulated by Atomoxetine in Healthy Volunteers , 2011, Biological Psychiatry.

[59]  Suzanne Fergus,et al.  Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues , 2011, Psychopharmacology.

[60]  I. Vardakou,et al.  Drugs for youth via Internet and the example of mephedrone. , 2011, Toxicology letters.

[61]  Karen McElrath,et al.  Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. , 2011, The International journal on drug policy.

[62]  A. Winstock,et al.  Mephedrone: still available and twice the price , 2010, The Lancet.

[63]  P. Schlattmann,et al.  Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. , 2010, Pharmacological research.

[64]  A. Dagher,et al.  Effect of d-amphetamine on inhibition and motor planning as a function of baseline performance , 2010, Psychopharmacology.

[65]  T. Klingberg Training and plasticity of working memory , 2010, Trends in Cognitive Sciences.

[66]  I. Heuser,et al.  Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. , 2010, Pharmacological research.

[67]  Martin Sarter,et al.  Phasic acetylcholine release and the volume transmission hypothesis: time to move on , 2009, Nature Reviews Neuroscience.

[68]  M. Talbot Brain gain: the underground world of neuroenhancing drugs. , 2009, New Yorker.

[69]  Young T. Hong,et al.  Dopamine Release in Dissociable Striatal Subregions Predicts the Different Effects of Oral Methylphenidate on Reversal Learning and Spatial Working Memory , 2009, The Journal of Neuroscience.

[70]  B. Sahakian,et al.  The mental wealth of nations , 2008, Nature.

[71]  M. Minzenberg,et al.  Modafinil: A Review of Neurochemical Actions and Effects on Cognition , 2008, Neuropsychopharmacology.

[72]  B. Maher,et al.  Poll results: look who's doping , 2008, Nature.

[73]  B. Sahakian,et al.  Professor's little helper , 2007, Nature.

[74]  T. Kelly,et al.  Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. , 2007, Experimental and clinical psychopharmacology.

[75]  R. Shelton,et al.  A Randomized, Double-Blind, Crossover Trial of Modafinil on Mood , 2007, Journal of clinical psychopharmacology.

[76]  S. McCabe,et al.  Illicit Use of Specific Prescription Stimulants Among College Students: Prevalence, Motives, and Routes of Administration , 2006, Pharmacotherapy.

[77]  T. Wilens Mechanism of action of agents used in attention-deficit/hyperactivity disorder. , 2006, The Journal of clinical psychiatry.

[78]  L. Johnston,et al.  Monitoring the Future national survey results on drug use, 1975-2018: Volume II, college students and adults ages 19-60 , 2005 .

[79]  L. Johnston,et al.  Monitoring the Future national survey results on drug use, 1975-2017: Volume I, secondary school students , 2005 .

[80]  Jonathan D. Cohen,et al.  An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.

[81]  J. Caldwell,et al.  Modafinil's effects on simulator performance and mood in pilots during 37 h without sleep. , 2004, Aviation, space, and environmental medicine.

[82]  U. Müller,et al.  Effects of modafinil on working memory processes in humans , 2004, Psychopharmacology.

[83]  M. Feeley,et al.  Effects of caffeine on human health , 2003, Food additives and contaminants.

[84]  J. Sallis,et al.  Effects of health-related physical education on academic achievement: project SPARK. , 1999, Research quarterly for exercise and sport.

[85]  E. Gould,et al.  Learning enhances adult neurogenesis in the hippocampal formation , 1999, Nature Neuroscience.

[86]  G. Gigerenzer,et al.  Specific attentional dysfunction in adults following early start of cannabis use , 1999, Psychopharmacology.

[87]  P. Reuter World drug report , 1998 .

[88]  J. Olney,et al.  Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin , 1998, Nature Medicine.

[89]  M. Gillman,et al.  Clinical role and mechanisms of action of analgesic nitrous oxide. , 1998, The International journal of neuroscience.

[90]  T. Robbins,et al.  “Paradoxical” effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology , 1979, Neuropharmacology.

[91]  T. Robbins,et al.  Are the effects of psychomotor stimulant drugs on hyperactive children really paradoxical? , 1977, Medical hypotheses.

[92]  Matej Sande Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users. , 2016, The International journal on drug policy.

[93]  W. Hall What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? , 2015, Addiction.

[94]  Patrick O'Malley,et al.  Monitoring the Future national survey results on drug use, 1975-2018: Overview, key findings on adolescent drug use , 2015 .

[95]  M. Evans-Brown,et al.  New Psychoactive Substances in Europe. An Update from the EU Early Warning System , 2015 .

[96]  F. Hickson,et al.  The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham , 2014 .

[97]  T. Robbins,et al.  Brain science, addiction and drugs , 2010 .

[98]  B. Christie,et al.  Environmental enrichment and voluntary exercise massively increase neurogenesis in the adult hippocampus via dissociable pathways , 2006, Hippocampus.

[99]  B. Sahakian,et al.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB , 2005, Psychopharmacology.

[100]  C. Ainsworth,et al.  Brain gain. , 2001, New scientist.